TITLE

Joint effort: NRC wants teamwork for home-health regs

AUTHOR(S)
Conn, Joseph
PUB. DATE
July 2011
SOURCE
Modern Healthcare;7/25/2011, Vol. 41 Issue 30, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that non-profit group National Research Council is calling on the U.S. Department of Health and Human Services' (HHS) Office of the National Coordinator (ONC) for Health Information Technology and the Food and Drug Administration (FDA) to work together to help ensure that information technology (IT)-reliant home-health devices are user-friendly. ONC is responsible for credentialing and regulating health information technology while FDA is responsible for regulating devices.
ACCESSION #
63547396

 

Related Articles

  • Healthcare IT proposal keeps oversight light. Conn, Joseph // Modern Healthcare;7/14/2014, Vol. 44 Issue 28, p14 

    The article offer information on the draft plan includes a three-tiered risk-based regulatory framework for healthcare information technology system and software and adds that the U.S. Food and Drug Administration would not regulate the complex and medication management software systems.

  • FDA calls for risk-rating health IT. Lee, Jaimy // Modern Healthcare;4/7/2014, Vol. 44 Issue 14, p13 

    The article reports that the U.S. Food and Drug Administration has proposed that the health information technology products should be classified on the basis of their potential risks to patient safety, as of April 2014 and presents views of Jeffrey Shuren of FDA on the proposal, as of April 2014.

  • A LIFE WITHOUT MEANINGFUL USE. Bassett, Mike // For the Record (Great Valley Publishing Company, Inc.);Oct2015, Vol. 27 Issue 10, p18 

    The article discusses the dissatisfaction and frustration of American hospitals and physicians with the meaningful use program. Topics include the role of stage 1 of meaningful use program in accelerating the adoption of electronic health records, the failure of stage 2 of the program to achieve...

  • FDA hints at statutory fix for 510(k) changes issue. McCARTY, MARK // Medical Device Daily;6/17/2013, Vol. 17 Issue 116, p1 

    The article highlights the subjects that were discussed at the U.S. Food and Drug Administration's (FDA) stakeholder meeting on the 510(k)-changes issue. Despite a pushback from the Congress, FDA representatives indicated that their interest in the issue has not waned. In fact, FDA regulatory...

  • FDA offers draft guidance for device 'pre-sub' program.  // Modern Healthcare;7/16/2012, Vol. 42 Issue 29, p4 

    The article reports that the U.S. Food and Drug Administration has issued draft guidelines to help medical device companies prior to submission of a product or research application.

  • Federal agencies propose health IT regulatory framework, seek stakeholder input and participation in new initiatives. Langowski, Mary B.; Ratcliff, Kristen E. // Venulex Legal Summaries;2014 Q2, following p1 

    The article provides a summary of the draft report that outlines a proposed strategy and recommendations for a risk based regulatory framework for health information technology. Topics discussed include the stakeholders' call for additional clarity on the regulation of the health IT industry,...

  • Face-to-face must wait: CMS delays enforcement of home health rule. Barr, Paul // Modern Healthcare;1/3/2011, Vol. 41 Issue 1, p12 

    The article reports that the U.S. Centers for Medicare and Medicaid Services has delayed the implementation of a rule which requires Medicare home health and hospice patients to meet face-to-face with a physician before qualifying for Medicare coverage.

  • EMRs, other tools count as medical devices.  // Healthcare Risk Management;Oct2011, Vol. 33 Issue 10, p116 

    No abstract available.

  • Draft Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products; Availability. Kux, Leslie // Federal Register (National Archives & Records Service, Office of;11/29/2012, Vol. 77 Issue 230, p71194 

    The article offers information about a notice issued by the U.S. Food and Drug Administration seeking comments regarding a draft document entitled "Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products," related to preclinical studies. It further...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics